Merck: Managing Vioxx (A)
|
|
- Aron Chase
- 5 years ago
- Views:
Transcription
1 APRIL 20, 2009 Merck: Managing Vioxx (A) Whatever decision we make is going to be based on the science and what's in the best interest of the patients. 1 Ray Gilmartin, 2004 In January 1999, pharmaceutical giant Merck and Co. s research pipeline was growing more robust as a result of increased research and development funding initiated by CEO Ray Gilmartin. New drug development was critical because patents on seven of Merck s bestselling drugs would expire in 2000 and 2001, representing an estimated 22% revenue loss for the company. 2,3 Furthermore, Merck s blockbuster anti-cholesterol drug, Zocor, was losing significant market share to competitor Pfizer s anti-cholesterol drug, Lipitor. One of the most promising drugs in Merck s pipeline was Vioxx, an arthritis and acute pain medication in the non-steroidal anti-inflammatory drug (NSAID) category. Compared to other NSAIDs such as aspirin, which could cause gastrointestinal (GI) damage if taken over extended periods of time, Vioxx had been shown to cause significantly less GI complications. Given the drug s unique properties and the size of its target population including 23 million arthritis sufferers in the U.S. alone 4 Gilmartin and other Merck executives hoped Vioxx would reinvigorate the firm s sales. Fueling the urgency to introduce Vioxx quickly, Pfizer had released a similar drug, Celebrex, just weeks earlier. As Gilmartin and the Merck team prepared to release Vioxx to the U.S. market, they wondered how valuable the drug could potentially be to Merck s future profitability. Merck: Merck was a global pharmaceutical firm that developed, manufactured, and marketed medicines and vaccines. Since its founding in 1891, Merck scientists had discovered numerous important medicines, including the first steroid cortisone in By 1999, the company employed 62,000 people including many PhDs and medical doctors in more than 100 countries. 5 1 Ilan Brat, Former Merck CEO Calls Vioxx Testing Thorough, The Wall Street Journal, August 10, This case draws heavily on the Report of John S. Martin to the Special Committee of the Board of Directors of Merck and Co., Inc. Concerning the Conduct of Senior Management in the Development and Marketing of Vioxx, September 5, 2006, Subsequent citations are abridged to Martin Report. 3 Martin Report, Appendix B, p Arthritis: Data and Statistics, National Center for Chronic Disease Prevention and Health Promotion, accessed September 17, Merck and Co., Inc., 1999 Annual Report, p. 1, and Merck and Co., Inc., Dain Rauscher Wessels, December 8, 1999, via Thomson ONE Banker, accessed April Professor Robert Simons and Research Associates Kathryn Rosenberg and Natalie Kindred prepared this case. This case was developed from published sources. HBS cases are developed solely as the basis for class discussion. Cases are not intended to serve as endorsements, sources of primary data, or illustrations of effective or ineffective management. Copyright 2009 President and Fellows of Harvard College. To order copies or request permission to reproduce materials, call , write Harvard Business School Publishing, Boston, MA 02163, or go to This publication may not be digitized, photocopied, or otherwise reproduced, posted, or transmitted, without the permission of Harvard Business School.
2 Merck: Managing Vioxx (A) Dr. Roy Vagelos, president and CEO of Merck from 1985 to 1994, was one in a long line of top Merck executives with a background in science and research who had been promoted from within. During Vagelos s tenure, Fortune Magazine voted Merck America s Most Admired Company for a record-breaking seven years in a row, creating a reputation for Merck as a great place to work. Although Merck was highly respected as a research leader in the pharmaceutical industry, the firm s stock price had dropped in the early 1990s, and revenues had flattened. (Exhibit 1 shows summary financial information from 1989 to 1993.) Enter Gilmartin In 1994, Ray Gilmartin (HBS MBA 68) was elected by the board of directors as Merck s president, chairman and CEO. An engineer by training, Gilmartin had spent the early years of his career at Eastman Kodak before becoming a consultant at Arthur Little. He later joined medical device manufacturer Becton Dickinson as vice president for strategy, and was appointed president and CEO of Becton Dickinson in To some, Gilmartin was an unusual, and possibly risky, choice: he lacked pharmaceutical experience and had run a company only a quarter the size of Merck. However, he had a reputation as a consensus-builder and his strengths dovetailed nicely with Merck s needs: Gilmartin had ushered Becton Dickinson through the price pressures of managed care in the mid-1980s and had boosted the firm s international profile. As Merck s CEO, Gilmartin reaffirmed the company s commitment to organic growth through investment in product R&D. At a time when many pharmaceutical companies were driving growth through mergers and acquisitions, Gilmartin argued that these actions offered only short-term gains in shareholder value while distracting employees and diluting the culture of the companies involved. Rather than pursuing growth through a merger, Gilmartin increased Merck s R&D budget dramatically (see Figure A). 6 Figure A Merck R&D Expenditures, ($ millions) $3,000 $2,000 $1,000 $ Source: Adapted from Merck and Co., Inc., 2003 Annual Report, p. 22. Soon after taking charge, Gilmartin called an off-site strategic planning meeting during which Merck s top managers articulated a research strategy for the years to come. They agreed to focus on developing drugs that met five criteria: drugs would target large patient populations; involve new 6 Merck Senior Management Stresses Strategy for Growth, Business Wire, December 12, 2005, accessed October 27,
3 Merck: Managing Vioxx (A) knowledge about the disease or the chemistry of the drug class; be taken orally; be taken once per day; and be specific to the target patient group and highly potent. 7 During his first five years at Merck, Gilmartin developed a reputation as a growth-oriented but responsible leader. (See Exhibit 2 for Merck financials from ) A Fortune magazine article reported, When employees describe Gilmartin, they use words like highly ethical and say he has a strong commitment to values. When confronted with difficult decisions, he is legendary for asking, What s the right thing to do? 8 Gilmartin was particularly fond of reminding Merck employees of the words spoken by former Merck president George W. Merck in 1950: We try never to forget that medicine is for the people. It is not for the profits. The profits follow, and if we have remembered that, they have never failed to appear. The better we have remembered it, the larger they have been. 9 Painkiller Drugs In the late 1990s, all classes of painkiller drugs had drawbacks. Narcotics (e.g., morphine) temporarily blocked severe pain, but were highly addictive. Local anesthetics (e.g., Novocain for dental work) numbed the immediate area, but the effects were short-lived. Non-steroidal antiinflammatory drugs or NSAIDs (e.g., aspirin and ibuprofen) suppressed certain pain-causing substances in the body, but could cause GI complications after extended use, including ulcers, stomach bleeding, and intestinal perforations. Notwithstanding potential GI complications, NSAIDs were the most prescribed class of painkiller in the U.S.: an estimated 45 million Americans received prescriptions for an NSAID in In addition, many NSAIDs were available over-the-counter (OTC), including aspirin, ibuprofen (Advil, Nuprin, and Motrin), and naproxen (Aleve). NSAIDs eased pain by suppressing the Cox enzyme, found at sites of pain and inflammation. In the early 1990s, scientists identified two different Cox enzymes: Cox-1 and Cox-2. Researchers hypothesized that GI complications were caused by suppression of the Cox-1 enzyme. Therefore, if a drug could be developed that suppressed only the Cox-2 enzyme a Cox-2 inhibitor it would alleviate pain without agitating the GI tract. Developing a Cox-2 Inhibitor In 1994, scientists working in a Merck research lab in Montreal discovered the rofecoxib molecule, a Cox-2 inhibitor. Merck Research Laboratories in New Jersey took this discovery and immediately began developing a selective NSAID painkiller. Merck scientists knew that Pfizer was working furiously to develop and market its own Cox-2-inhibiting painkiller. Many believed the first firm to introduce a Cox-2 inhibitor would reap significant advantages; Merck s marketing department valued the advantage at $611 million Neff, Thomas J & James M. Citrin with Paul Brown, Lessons From The Top: The Search for America s Best Business Leaders, (New York: Doubleday, 1999), p Lee Clifford, Tyrannosaurus Rx, Fortune, 142, no. 10, October 30, Executive speech by George W. Merck at the Medical College of Virginia at Richmond, December 1, Martin Report, Appendix A: Sections A-G, p Martin Report, Appendix B, p. 7. 3
4 Merck: Managing Vioxx (A) Celebrex Pfizer won the race and released its Cox-2 inhibitor, trade-named Celebrex, in January Sales of the drug broke records immediately: within two weeks, Celebrex had captured 6% of the arthritis-pain prescription market. 12 With other blockbuster drugs in its portfolio, including Lipitor and Viagra, Pfizer was cash-rich and in an excellent position to market Celebrex aggressively. By May 1999 only four months after its introduction more than 2.8 million prescriptions for Celebrex had been dispensed. 13 Vioxx In May 1999, four months after the launch of Pfizer s Celebrex, Merck released its own Cox-2 inhibitor to the U.S. market under the trade-name Vioxx. The drug, which was marketed to arthritis sufferers, met all of the objectives set forth at the 1994 strategy meeting: Vioxx targeted large patient populations; involved new knowledge about advanced chemistry; was taken once per day orally; was highly potent; and targeted specific pain attributes. Merck supported Vioxx s launch with an extensive promotional campaign, spending $102 million in 1999 on visits by Merck sales representatives to physicians offices (as many as 150,000 visits per month). 14 To educate the sales reps about the new drug, Merck developed a training game called Dodge Ball Vioxx, based on the popular television game show, Family Feud. The game was designed to prepare representatives to respond accurately to physicians questions or concerns using claims approved by the U.S. Food and Drug Administration (FDA). During the training exercise, sales reps were split into teams and drew cards containing questions that doctors might ask about Vioxx (e.g., I am concerned about the cardiovascular effects of Vioxx ). To earn points, players were required to answer questions correctly using FDA-approved language to describe the drug s benefits and risks; to make the game more interesting, if a player picked a card that said Dodge, the player was allowed to skip his or her turn and earn an additional point. 15 From May through December 1999, doctors wrote more than five million prescriptions for Vioxx. The drug s release was, according to Merck s 1999 annual report, the company s biggest, fastest, and best launch ever; indeed, Vioxx sales generated the majority of the $578 million Merck earned in 1999 in its anti-inflammatory/analgesics line of business. 16 Vioxx s patent was set to expire in The VIGOR Trial On March 9, 2000 when Vioxx had been on the market for less than one year the results of a clinical trial on Vioxx were released to Merck. The trial, called VIGOR (for Vioxx Gastrointestinal Outcomes Research), was designed to compare GI adverse events, such as ulcers and internal bleeding, for rheumatoid arthritis patients taking Vioxx versus another painkiller; Merck elected to compare Vioxx to naproxen (OTC brand-name Aleve). As Gilmartin and his team had hoped, VIGOR confirmed that Vioxx decreased the risk of GI complications relative to naproxen: patients taking naproxen in the trial were more than twice as likely to suffer a serious GI event than those taking Vioxx. However, the data also indicated that patients taking Vioxx were twice as likely to have a serious cardiovascular event, such as a heart attack, compared to those taking naproxen. (See Table A for the results of the VIGOR trial.) 12 Prescriptions for Monsanto s Celebrex Soared to 55,000 in 2 nd week, Dow Jones Business News, February 1, An Uphill Battle (Vioxx, Merck s Antiarthritic Product), Med Ad News, 18, no. 6, June 1, Milton Liebman, Head-to-head marketing may the best-promoted drug win, Medical Marketing and Media, Vol. 35, Issue 11, November 1, Barbara Martinez, Merck explains documents, The Wall Street Journal, November 15, Merck 10-K and Annual Report, via Thomson Research, accessed July Merck Wins U.S. Patent Interference Proceeding on VIOXX, Business Wire, October 4,
5 Merck: Managing Vioxx (A) Table A VIGOR Trial Results (2000) Patients with Events Relative Risk of Naproxen vs. Vioxx Type of Adverse Event (AE) Treatment Group Patient Years a Rates of Adverse Events Complicated upper GI AEs Vioxx % 2.33 Naproxen % GI Bleeding Vioxx % 2.73 Naproxen % All serious Cardiovascular AEs Vioxx % 0.50 Naproxen % Source: Adapted from Martin Report, Appendix E, p. 2. a Patient Years was calculated by multiplying the number of patients by the duration of their participation in the trial. It was used to ensure the statistics generated were comparable to one another, despite the number of participants in each treatment group. Analyzing the Results While pleased that the VIGOR trial indicated that Vioxx was more GI-safe than naproxen, scientists at Merck Research Laboratories (MRL) were alarmed by the relative incidence of cardiovascular events for subjects taking Vioxx. The unexpected results raised several questions. Was some aspect of Vioxx increasing the risk of cardiovascular complications? Or, alternatively, was naproxen doing something similar to aspirin to prevent heart attacks? (Since the 1980s, many physicians had recommended taking low doses of aspirin to patients at higher risk for stroke and heart attack.) Dr. Ed Scolnick, president of Merck Research Labs, asked his scientists to undertake a thorough analysis not only of the VIGOR trial, but of all Vioxx trials and studies that had been completed to date. In addition, he initiated research on naproxen to learn about the drug s possible cardioprotective, or heart-helping, effects. Third, Scolnick wanted to investigate whether the population in the VIGOR trial patients with rheumatoid arthritis might be more prone to heart attacks than other patient populations. 18 To achieve these objectives, MRL scientists reanalyzed data from pre-fda approval studies of Vioxx. Their findings confirmed their initial conclusions: no statistically significant difference in cardiovascular events existed between Vioxx, placebo, and the comparator NSAIDs. 19 MRL then sought to determine whether Vioxx was causing adverse cardiovascular events or if naproxen was preventing them. To explore this hypothesis, Scolnick decided to unblind some data from an in-progress, placebo-controlled study investigating the possible use of Vioxx to treat Alzheimer s disease. The scientists collected cardiovascular data for treatment group A and treatment group B without knowing which group was taking Vioxx and which the placebo. 20 (Table B shows the partially unblinded results.) The trial s results did not indicate a statistically significant difference in cardiovascular risk for patients taking Vioxx versus a placebo Martin Report, Appendix E, p Martin Report, Appendix E, p Martin Report, Appendix E, p When these studies were concluded, it was revealed that Vioxx was Treatment Group A. 5
6 Merck: Managing Vioxx (A) Table B Summary of Serious Cardiovascular Adverse Events: Vioxx Protocols 091 and 078 Treatment Group A Treatment Group B N = 1050 N = 1050 n % n % All Cardiovascular Adverse Events % % Serious Adverse Events, such as heart attack and stroke % % Source: Adapted from Martin Report, Appendix E, p. 4. MRL next examined if naproxen, like aspirin, might have cardioprotective qualities. In their investigation, scientists at MRL uncovered only limited evidence to support the cardioprotection hypothesis for naproxen. No specific clinical trials had been conducted on the question, 22 but several articles and small studies indicated naproxen had some anti-clotting properties, similar to aspirin, when used continuously. Though scarce, the data offered some support for the naproxen cardioprotection theory. 23 The MRL scientists last set of analyses focused on the rheumatoid arthritis patients in the VIGOR trial. While some evidence showed that rheumatoid arthritis patients had an increased risk of cardiovascular disease, the data was not sufficient to explain the difference in cardiovascular events between patients taking Vioxx and naproxen. 24 Response to the VIGOR Trial When MRL s analysis of VIGOR and previous trials concluded in March 2000, Scolnick s MRL team and Merck s senior executives were satisfied as to the safety and efficacy of Vioxx. MRL submitted preliminary information to the FDA about the VIGOR trial on March 23, 2000, and issued a worldwide press release concerning VIGOR on March 27, (See Exhibit 3 for the press release.) In June 2000, Merck applied to the FDA for a Vioxx label revision to incorporate the VIGOR trial s findings, both regarding the drug s favorable GI profile and the possible cardiovascular risks associated with using Vioxx versus naproxen. The revised information if approved by the FDA would serve to warn both physicians and patients of potential adverse effects and highlight the perceived benefits of the drug. 25 Such a label revision would provide Merck with an important market advantage: none of Merck s competitors had proven that their drug increased GI safety versus non-selective NSAIDs (although this quality had been hypothesized as a class effect for Cox-2 inhibitors). As a result, no drug maker had been permitted by the FDA to claim increased GI safety on their product labels. The revised label for Vioxx was approved in April Martin Report, Appendix E, p Martin Report, Appendix E, p Martin Report, Appendix E, p For drug producers, the import of prescription drug labels extended beyond conveying information, such as dosage instructions, to consumers. Producers could only market drugs for uses approved by the FDA to be included on the drug label (i.e., relieving severe pain, reducing inflammation); therefore, the usages that drug producers were permitted to include in a prescription label could dramatically affect the drug s sales. 6
7 Merck: Managing Vioxx (A) Outlook In 2003, product development remained a top priority for Merck. The firm submitted two new drug applications to the FDA, but also discontinued two drugs in late-stage clinical trials due to safety and efficacy concerns. Adding to the company s performance pressure, the patent for Zocor, Merck s bestselling drug with $5 billion in annual revenue, was set to expire in In a move to cut costs and streamline the firm s focus, Merck laid off more than 4,400 employees. Vioxx contributed $2.5 billion in 2003 to worldwide sales. 26 Generating more than 91 million prescriptions in the U.S. alone, Vioxx had reached $2 billion in sales faster than any drug in Merck s history. 27 Sales growth had been slowing, however. In 2003, Vioxx posted only a 2% sales gain over 2002; Pfizer s Celebrex experienced similar limits to growth. The slowdown was attributed, in part, to the launch of Bextra Pfizer s next-generation Cox-2 inhibitor but also to fears over recurring cardiovascular warnings for Cox-2 inhibitors. Looking forward, executives at Merck speculated over the potential value that Vioxx could bring to the company and how competition and consumers concerns over cardiovascular risks might affect the drug s future sales. (See Exhibit 4 for Merck s product sales and Exhibit 5 for the firm s consolidated income statement.) 26 Vioxx sales had ranged from $2 billion to $2.5 billion since Merck and Co., Inc., 2003 Annual Report, p. 19; Ricardo Alonzo-Zalvidar, Vioxx Risks not Part of Sales Pitch, Files Reveal, Los Angeles Times, May 6, 2005, accessed November 20,
8 Merck: Managing Vioxx (A) Exhibit 1 Summary Financial Information, ($ millions except EPS and share price) Net sales 6,551 7,672 8,603 9,663 10,498 Net income (loss) 1,495 1,781 2,122 1,984 2,166 Market Value 30,644 34,781 64,354 49,651 43,104 Book Value 3,521 3,834 4,916 5,003 10,022 EPS a Share Price (High) Share Price (Low) Source: Standard and Poor s Compustat data via Research Insight, accessed July a EPS: Fully diluted, including extraordinary items. Exhibit 2 Summary Financial Information, ($ millions except EPS and share price) Net sales 14,970 16,681 19,829 23,637 26,898 32,714 Net income (loss) 2,997 3,335 3,881 4,614 5,248 5,891 Market Value 47,573 80,643 96, , , ,046 Book Value 11,139 11,736 11,971 12,614 12,802 13,242 EPS a Share Price (High) Share Price (Low) Source: Standard and Poor s Compustat data via Research Insight, accessed July a EPS: Fully diluted, including extraordinary items. 8
9 Merck: Managing Vioxx (A) Exhibit 3 VIGOR Press Release, March 27, 2000 Merck Informs Investigators of Preliminary Results Of Gastrointestinal Outcomes Study with VIOXX News Release WEST POINT, Pa., March 27, 2000 Merck & Co., Inc. today informed its investigators of a preliminary analysis from a large gastrointestinal (GI) outcomes study that compared Vioxx (rofecoxib) with naproxen in patients with rheumatoid arthritis. Among patients treated with Vioxx, there was a significantly reduced incidence of serious gastrointestinal events compared to patients treated with naproxen. Merck plans to submit the information to the U.S. Food and Drug Administration (FDA) and other regulatory agencies worldwide in the next few months. In addition, significantly fewer thromboembolic events were observed in patients taking naproxen in this GI outcomes study, which is consistent with naproxen s ability to block platelet aggregation. This effect on these events had not been observed previously in any clinical studies for naproxen. Vioxx, like all COX-2 selective medicines, does not block platelet aggregation and therefore would not be expected to have similar effects. As a result, Merck is notifying investigators, who are conducting other Merck studies with Vioxx or another investigational medicine in the same class, of protocol amendments to allow the addition of low-dose aspirin where appropriate. Patients using low-dose aspirin, which also blocks platelet aggregation, were excluded from the GI outcomes study. Vioxx does not interfere with the ability of low-dose aspirin to block platelet aggregation. The completed study, called VIGOR (Vioxx Gastrointestinal Outcomes Research) compared the GI safety of Vioxx (50 mg once daily) to prescription-strength naproxen (500 mg twice a day) in approximately 8,000 patients with rheumatoid arthritis. The study specifically assessed the incidence of certain types of clinically significant upper GI events, including perforations, ulcers, obstructions and bleeds. Naproxen is a commonly used non-steroidal anti-inflammatory drug (NSAID) indicated for the treatment of a number of arthritic diseases, including rheumatoid arthritis. Vioxx is not approved for the treatment of rheumatoid arthritis, nor is an application for this use under review. Vioxx is approved in the U.S. for the relief of the signs and symptoms of osteoarthritis, management of acute pain in adults and treatment of menstrual pain. Researchers believe that NSAIDs work by inhibiting two related enzymes: COX-1, the enzyme that helps maintain the stomach lining and promotes platelet aggregation, and COX-2, the enzyme that triggers pain and inflammation. At therapeutic doses, Vioxx works by selectively inhibiting COX-2 without inhibiting COX-1; non-selective NSAIDs like naproxen inhibit both COX-1 and COX- 2. Medicines like aspirin and naproxen that significantly inhibit COX-1 block platelet aggregation and therefore have the potential to provide cardioprotection. An extensive review of safety data from all other completed and ongoing clinical trials, as well as the post-marketing experience with Vioxx, showed no indication of a difference in the incidence of Thromboembolic events between Vioxx, placebo, and comparator NSAIDs. Further analyses are ongoing, and final results of the GI outcomes study with Vioxx will be presented at peer-reviewed medical meetings this year. 9
10 Merck: Managing Vioxx (A) Important information about Vioxx The recommended dose of Vioxx for the treatment of osteoarthritis is 12.5 mg once daily. Some patients may receive additional benefit by increasing the dose to 25 mg once daily. Serious stomach problems, such as bleeding, can occur without warning symptoms. Administration of low-dose aspirin with Vioxx may result in an increased rate of GI ulcers or other complications compared to use of Vioxx alone. Physicians and patients should remain alert for signs and symptoms of gastrointestinal bleeding. Common side effects reported in osteoarthritis clinical trials with Vioxx were upper-respiratory infection, diarrhea, nausea and high blood pressure. People who have had an allergic reaction to Vioxx, aspirin or other NSAIDs should not take Vioxx. Safety and effectiveness in children below the age of 18 have not been studied. Merck & Co., Inc. is a global, research-driven pharmaceutical company that discovers, develops, manufactures and markets a broad range of human and animal health products, directly and through its joint ventures, and provides pharmaceutical benefit services through Merck-Medco Managed Care. Source: Martin Report, Appendix E, p
11 Merck: Managing Vioxx (A) Exhibit 4 Merck Product Sales by Category, ($ millions) Product Category * Atherosclerosis (elevated cholesterol) a 5, , , ,077.9 Hypertension/Heart Failure b 4, , , ,421.6 Anti-inflammatory/analgesics c 2, , , ,677.3 Osteoporosis d 1, , , ,676.6 Vaccines/biologicals , , ,056.1 Respiratory , , ,009.4 Antibiotics/anti-fungal ,028.5 Ophthalmologicals Anti-ulcerants/Urology Human immunodeficiency virus (HIV) Other Merck products 1, , ,967.3 Merck-Medco 20, , , Total Sales $40,363.2 $47,715.7 $51,790.3 $22,485.9 Total Sales Excluding Merck-Medco 20, , , ,485.9 Source: Adapted from Merck Annual Reports. *Merck spun out Merck-Medco, its pharmacy benefit management division, in a Products include Zocor and Mevacor. b Products include Vasotec, Cozaar, Hyzaar, Prinivil and Vaseretic. c Vioxx generated approximately 90% of the revenue in this category. d Fosamax is the only product in this category. Exhibit 5 Merck Consolidated Income Statement, ($ millions) Income/Expenses a Materials & Production 22, , , ,315.3 Marketing & Administrative 6, , , ,394.9 Research & Development 2, , , ,178.1 Equity income from affiliates (764.9) (685.9) (644.7) (474.2) Other (income) expense, net (221.1) Total Expenses 30, , , ,193.0 Income from continuing operations before taxes 9, , , ,292.9 Taxes on income 3, , , ,462.0 Net Income 6, , , ,830.9 Source: Adapted from Merck Annual Reports. a Merck spun out Merck-Medco, its pharmacy benefit management division, in
Attention Pain Sufferers. Advil-Aleve-Bayer-Celebrex-DemerolMotrin-Naproxen-Oxycontin- PercocetToradol-Tylenol-Ultram-Vicodin-Voltaren...
From the desk of Kris Belfry Enerkinetics Natural Health Care 2684 Los Palmas Crt. Mississauga, On L5N 2G7 (416) 627 3455 "If someone wishes for good health, one must first ask oneself if he is ready to
More information61 Recommendations for better use of medications
Chapter 61 Recommendations for better use of medications As stated elsewhere in this book, we are fortunate to have a number of effective medications for treatment of many medical conditions. The drug
More informationREDUCE THE HURT REDUCE THE HARM
IF YOU HAVE OSTEOARTHRITIS (OA) OR RHEUMATOID ARTHRITIS (RA) REDUCE THE HURT AND REDUCE THE HARM DUEXIS reduces the risk of developing stomach ulcers for patients who are taking ibuprofen for OA/RA INDICATIONS
More informationA PATIENT GUIDE FOR MANAGING PAIN
A PATIENT GUIDE FOR MANAGING PAIN PAIN MANAGEMENT Knowing the Facts Pain can be controlled. Pain is common after surgery and with many types of illnesses. Most patients with acute and chronic pain can
More informationMerrill Lynch Healthcare Conference New York
Merrill Lynch Healthcare Conference New York Matthew Emmens Chief Executive Officer February 3, 2004 A Strategic Review Today and Beyond Clear Strengths Highly successful business model Strong pipeline
More informationGalvus US NDA Approvable - Overview
Galvus US NDA Approvable - Overview Galvus NDA filed with FDA Jan 2006 PDUFA action date extended by 3 months until February 26th 2007 Significant new clinical data added to NDA - Approximately 1000 patient
More informationSumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical
For immediate release November 25, 2004 Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical Sumitomo Chemical Co., Ltd. announced today that its subsidiary, Sumitomo
More informationSPECIALTY MEDICAL CANNABIS COMPANY
SPECIALTY MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - August 2018 ReviveThera.com Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com Forward
More information1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes
1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements
More informationFORM8-K HILLENBRAND,INC.
UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d)oftheSecuritiesExchangeActof1934 Date of Report (Date of earliest event reported): December18,2015
More informationPain therapeutics. Acetaminophen/NSAIDs Acute pain Osteoarthritis Migraine Acute Gout Neuropathic pain
Pain therapeutics Acetaminophen/NSAIDs Acute pain Osteoarthritis Migraine Acute Gout Neuropathic pain James McCormack, Pharm.D. Professor Faculty of Pharmaceutical Sciences, UBC Common types of pain killers
More informationFebruary 23, Q4 and Year-End 2016 Financial Results
February 23, 2017 Q4 and Year-End 2016 Financial Results 2 RETHINKING CNS Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Jim Doherty, Ph.D.,
More informationPain Control After Surgery. Patient Information
Pain Control After Surgery Patient Information What is Pain? Pain is an uncomfortable feeling that tells you something may be wrong in your body. Pain is your body s way of sending a warning to your brain.
More informationSPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator
More informationHOW TO MAXIMIZE PATIENT RECRUITMENT IN ONCOLOGY TRIALS A BIOPHARMA DIVE PLAYBOOK
HOW TO MAXIMIZE PATIENT RECRUITMENT IN ONCOLOGY TRIALS A BIOPHARMA DIVE PLAYBOOK Over the last several decades, patient recruitment for clinical trials has remained a major barrier to rapid execution of
More informationWhats better for inflammation ibuprofen or aleve
Whats better for inflammation ibuprofen or aleve The Borg System is 100 % Whats better for inflammation ibuprofen or aleve Patients were randomly allocated to receive either naproxen or ibuprofen first
More informationSPECIALTY MEDICAL CANNABIS COMPANY
SPECIALTY MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - August 2018 ReviveThera.com Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com Forward
More informationMEDICAL CANNABIS COMPANY
MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - June 2018 ReviveThera.com Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com Forward looking statements
More informationGLOBAL NEUROSTIMULATION MARKET
GLOBAL NEUROSTIMULATION MARKET R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p o r t s A b o u t M a r k e t s a n d
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationBank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt. September 14, 2011
Bank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt Chairman of the Board of Management of Bayer HealthCare AG and Chairman of the Bayer HealthCare Executive Committee
More informationWalgreens (WAG) Analyst: Juan Fabres Fall 2014
Recommendation: Buy Target Price August 31, 2016: $77.57 1. Reasons for the Recommendation With the acquisition of Alliance Boots in Europe, Walgreens will be the first US pharmacy to operate retail stores
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationCEO Operational Report. Annual General Meeting 23 October 2013
CEO Operational Report Annual General Meeting 23 October 2013 Leading the Field Clinical Trials Axon Sports Cogstate Research COGNIGRAM Playing an integral role in cognition-related clinical trials Cutting
More information2. Develop teams of four students (there are seven unique roles in ABIG Company).
ROLE-PLAY EXERCISE QRS AsthmaCare Products, Inc. PROCESS 1. Make copies of the role-play exercise pages (one copy of background page for each student in the class; one set of four roles for every four
More informationArkadin Managed Calls
Arkadin Managed Calls ThromboGenics Conference Call FY 2017 Business Update & Results Thursday 15.03.2018 18u30 CET Speakers: Patrik De Haes, MD, CEO and Dominique Vanfleteren, CFO Call Duration: 19:05
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Celebrex) Reference Number: CP.CPA.239 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationRimoxen. Rimoxen! "The Gastro and Cardio friendly anti-inflammatory ingredient"
Rimoxen A Botanical Anti-Inflammatory COX-2 Selective Ingredient Question: How doses Rimoxen compare to the prescription COX-2 inhibitors (Vioxx and Celebrex) and the OTC NSAID pain relievers such as aspirin
More informationREFERENCE CODE GDHC282DFR PUBLICATION DATE OCTOBER 2013 BELVIQ (OBESITY) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC282DFR PUBLICATION DATE OCTOBER 2013 BELVIQ (OBESITY) - Executive Summary Below table provides a summary of Belviq for obesity in the nine major pharmaceutical markets during the forecast
More informationLEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017
LEERINK GLOBAL HEALTHCARE CONFERENCE Marino Garcia EVP, Chief Strategy Officer February 15, 2017 SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting
More informationMyriad Genetics Fiscal First-Quarter 2019 Earnings Call 11/06/2018
Myriad Genetics Fiscal First-Quarter 2019 Earnings Call 11/06/2018 Copyright 2017 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Forward Looking Statements
More information27 th Annual J.P. Morgan Healthcare Conference. January 13, 2009
27 th Annual J.P. Morgan Healthcare Conference January 13, 2009 1 Forward Looking Statements This presentation and any subsequent Q&A may contain forward-looking statements, including with respect to:»
More informationPresentation to AGM 9 November Deborah Rathjen CEO & Managing Director
Presentation to AGM 9 November 2011 Deborah Rathjen CEO & Managing Director Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward looking" statements within the
More informationManagementStudyGuide.com. Visit https://grandemareopenseatoknowledge.wordpress.com/
BCG Matrix Contents? Emergence of BCG Matrix Approaches of BCG Matrix Components of BCG Matrix Applications of BCG Matrix Advantages of BCG Matrix Limitations of BCG Matrix Emergence of Portfolio Matrices
More informationNSAIDs. NSAIDs are important but they can have side effects.
NSAIDs Pain Treatment Nonsteroidal anti-inflammatory drugs (NSAIDs) are often recommended for initial treatment of pain and can be added to more powerful drugs to treat worse pain. Acetaminophen, such
More informationCan i take indomethacin with aspirin
Can i take indomethacin with aspirin The Borg System is 100 % Can i take indomethacin with aspirin People who take nonsteroidal anti-inflammatory drugs (NSAIDs) (other than aspirin ) such as indomethacin
More informationCompany presentation. SEB Nordic Seminar Bella Sky, Copenhagen. Carsten Hellmann, President & CEO 9 January 2018
Company presentation SEB Nordic Seminar Bella Sky, Copenhagen Carsten Hellmann, President & CEO 9 January 2018 Allergy: a global disease with a large unmet need >500 million people affected by allergic
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationCOX-2 inhibitors: A cautionary tale. October 2, 2006
COX-2 inhibitors: A cautionary tale October 2, 2006 Molecular interventions in human disease... An approach as old as human civilization. With whom the herbs have come together Like kingly chiefs unto
More informationAvenue Therapeutics, Inc. August 2016
Avenue Therapeutics, Inc. August 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe
More informationManaging Osteoarthritis Pain With Medicines. A Review of the Research for Adults
Managing Osteoarthritis Pain With Medicines A Review of the Research for Adults Is This Summary Right for Me? Yes, if: A doctor* said you have osteoarthritis (pronounced ah-stee-oharth-rye-tis). Osteoarthritis
More informationSG Cowen 23rd Annual Health Care Conference March 18, Shire Pharmaceuticals Group plc
SG Cowen 23rd Annual Health Care Conference March 18, 2003 Shire Pharmaceuticals Group plc THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein
More informationDaiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Duexis) Reference Number: CP.PMN.120 Effective Date: 06.01.18 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationAvenue Therapeutics, Inc. September 2016
Avenue Therapeutics, Inc. September 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the
More informationDARA Reports Year-End 2012 Financial Results
April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,
More informationCan Ibuprofen Stop Your Period For A Few Hours
Can Ibuprofen Stop Your Period For A Few Hours The sad news is that you can't stop it once it starts, but you certainly can try ways to make In a few cases, ibuprofen puts an end to the period altogether.
More informationAvenue Therapeutics, Inc. May 2017
Avenue Therapeutics, Inc. May 2017 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe
More informationAStoryofSunPharmaceuticalsLaboratoriesGoingGlobal
Global Journal of HUMANSOCIAL SCIENCE: E Economics Volume 18 Issue 4 Version 1.0 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Online ISSN: 2249460x & Print
More informationTips for Pain Management
Tips for Pain Management Going for the 3 Increases: Increase in Health, Increase in Happiness & Increase in Energy Strategies for Success in Health Management By: James J. Messina, Ph.D. What are the medical
More informationCopyright 2017 BioStar Nutrition Pte Ltd. All rights reserved. Published by Adam Glass.
CardioClear7.com 1 Copyright 2017 BioStar Nutrition Pte Ltd All rights reserved Published by Adam Glass. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any
More informationCochlear Limited 2017 Annual General Meeting Chairman s Address
Cochlear Limited 2017 Annual General Meeting Chairman s Address 17 October 2017 Rick Holliday-Smith Chairman Ladies and gentlemen Financial results Cochlear reported a record net profit of $224 million,
More informationCoventry Health Care of Georgia, Inc.
Coventry Health Care of Georgia, Inc. PRESCRIPTION DRUG RIDER (for High Deductible Health Plans) This Prescription Drug Rider is an attachment to the Coventry Health Care of Georgia, Inc. ( Health Plan
More informationAVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018
AVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning
More informationSafe, effective, affordable drug choices: online tool for payers and patients.
Executive summary: Rising healthcare costs and greater access to medical information drive patients to seek options for their drug therapy. The MedAlternatives database by Gold Standard/Elsevier empowers
More informationSupernus Pharmaceuticals
Supernus Pharmaceuticals Jefferies 2016 Healthcare Conference May 2016 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include
More informationAssociation of American Cancer Institutes
Association of American Cancer Institutes Statement by the Association of American Cancer Institutes on Fiscal Year (FY) 2016 Appropriations for the Department of Health and Human Services Subcommittee
More informationUCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam
UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of partial-onset seizures in epilepsy Primary efficacy and safety data from the
More informationSynergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation
January 19, 2017 Synergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals
More informationMedia Contacts: Kelley Dougherty Investor Contact: Graeme Bell (215) (908)
News Release Media Contacts: Kelley Dougherty Investor Contact: Graeme Bell (215) 652-0059 (908) 423-5185 Janet Skidmore (267) 305-7715 Merck Launches National Advertising Campaign for GARDASIL, Merck's
More informationInvestor Presentation March 2015
Investor Presentation March 2015 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking statements within the
More informationLauren Silvernail, CFO & VP Corporate Development to present at 2005 Thomas Weisel Partners Healthcare Conference on September 7, 2005 at 3:50 pm EST
Lauren Silvernail, CFO & VP Corporate Development to present at 2005 Thomas Weisel Partners Healthcare Conference on September 7, 2005 at 3:50 pm EST Forward Looking Statements Certain statements contained
More informationWalgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs
Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion
More informationNEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan
NEWS RELEASE Media Contact: Megan Pace 650-467-7334 Investor Contact: Kathee Littrell 650-225-1034 Patient Inquiries: Ajanta Horan 650-467-1741 GENENTECH RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR
More informationMedia Contacts: Amy Rose Investor Contact: Graeme Bell (908) (908)
News Release FOR IMMEDIATE RELEASE Media Contacts: Amy Rose Investor Contact: Graeme Bell (908) 423-6537 (908) 423-5185 Tracy Ogden (267) 305-0960 FDA Approves Once-Daily JANUVIA, the First and Only DPP-4
More informationObsEva Reports First Quarter 2018 Financial Results and Provides Business Update
ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update -Key First Quarter 2018 Clinical Milestones Achieved Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationGlobal Pulse Oximetry Project
3.3 Introduction of new health technologies: lessons learned Over the past twenty years there have been a number of comprehensive public health projects which illustrate important lessons regarding the
More informationBioCryst Pharmaceuticals
BioCryst Pharmaceuticals Jefferies 2010 Global Life Sciences Conference New York Stuart Grant Senior Vice President & Chief Financial Officer Rob Bennett Executive Director, Investor Relations & Business
More informationThe Dental Corporation Opportunity
The Dental Corporation Opportunity for Practice Principals. It s the perfect professional collaboration. You focus on dentistry, we look after the paperwork. In recognition of what you, the Practice Principal,
More informationAgenda 2030: One Nation Labour s Plan for science Response from Alzheimer s Research UK
Agenda 2030: One Nation Labour s Plan for science Response from Alzheimer s Research UK 1. Introduction 1.1. Alzheimer s Research UK is the UK s leading dementia research charity. As research experts,
More informationTheravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation
Theravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation TD-1211 Achieves Primary and Secondary Endpoints SOUTH SAN FRANCISCO,
More informationFlexion Therapeutics Reports First-Quarter 2018 Financial Results and Recent Business Highlights
May 8, 2018 Flexion Therapeutics Reports First-Quarter 2018 Financial Results and Recent Business Highlights Company booked net ZILRETTA sales of $2.2 million in Q1 Positive developments in Medicare reimbursement
More informationEU5 Bariatric Surgery Procedures Outlook to 2020
EU5 Bariatric Surgery Procedures Outlook to 2020 Reference Code: GDMECR0089PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...
More informationEgalet Corporate Presentation
Egalet Corporate Presentation Specialty Pharmaceutical Company Focused on Pain 1 NASDAQ: EGLT Forward-Looking Statements Statements included in this presentation that are not historical in nature are "forward-looking
More informationThe revolutionary new supplements from America s foremost expert in Joint Health.
AVOSOY Products from Dr. Theo s Official The revolutionary new supplements from America s foremost expert in Joint Health. AVOSOY Products are powerful dietary supplements for joint health. They contain
More informationAsprin Bryce Gates Richard hammond Agustin chavez
Asprin Bryce Gates Richard hammond Agustin chavez Who discovered asprins? The discovery of aspirin is customarily said to have resulted from Felix Hoffmann's rheumatic father encouraging his son to produce
More informationRULES OF CONDUCT OF INSIDERS RESPECTING
T RULES OF CONDUCT OF INSIDERS RESPECTING RADING O F SECURITIES OF TFI International lnc. Amended and restated July 2015 Executive Summary As an insider of TFI International Inc. ( TFI International )
More informationIncrease in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
More informationSlide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO
Slide 1 Lars Fruergaard Jørgensen President and CEO Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the company
More informationSlide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A
Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or
More informationCelecoxib Powder, Diclofenac Powder, Flurbiprofen Powder, Ibuprofen Powder, Ketoprofen Powder, Meloxicam Powder, Tramadol Powder
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.02.26 Subject: Anti-Inflammatory Pain Powders Page: 1 of 5 Last Review Date: December 3, 2015 Anti-Inflammatory
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Policy Reference Number: CP.PMN.53 Effective Date: 09.12.17 Last Review Date: 11.18 Line of Business: Medicaid, HIM-Medical Benefit Revision Log See Important Reminder at the end of this
More informationCONCERNED ABOUT TAKING OPIOIDS AFTER SURGERY?
CONCERNED ABOUT TAKING OPIOIDS AFTER SURGERY? ASK YOUR DOCTOR ABOUT EXPAREL FOR LONG-LASTING, NON-OPIOID PAIN RELIEF. VISIT EXPAREL.com/patient FOR MORE INFORMATION. YOU HAVE A SAY IN HOW YOUR PAIN IS
More informationAfter simple testing that only takes minutes people with elevated test results are then recommended to see their physicians for follow-up.
New Medical Device Company Addresses Two Very High Demand Markets with its Proprietary Products. Trader Tracks likes this company as they provide reasonably priced equipment and testing while medical costs
More informationSAMPLE. Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to Reference Code: GDME0166BDB
Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0166BDB Publication Date: January 2013 GlobalData. This report is a licensed product
More informationAVOSOY Products from Dr. Theo s Official
AVOSOY Products from Dr. Theo s Official The revolutionary new supplements from America s foremost expert in Joint Health. AVOSOY Products are powerful dietary supplements for joint health. They contain
More informationINTERIM MANAGEMENT STATEMENT Q3 2017
INTERIM MANAGEMENT STATEMENT Q3 2017 Significant progress across all clinical programs New pre-clinical immunooncology data to be presented during R&D Day in New York Research & Development highlights:
More informationInnovative Nuclear Receptor Modulation Medicine
Innovative Nuclear Receptor Modulation Medicine Dale C Leitman, M.D., Ph.D. Isaac Cohen, O.M.D., Ph.D. October 2015 Corporate Mission Iaterion, Inc. is Developing Novel Pharmaceutical Nuclear Receptor
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: No Coverage Criteria/Off-Label Use Policy Reference Number: CP.PMN.53 Effective Date: 07.01.18 Last Review Date: 05.01.18 Line of Business: Oregon Health Plan Revision Log See Important
More informationREFERENCE CODE GDHC1032FPR PUBLICAT ION DATE M ARCH 2014 PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES - CURRENT AND FUTURE PLAYERS
REFERENCE CODE GDHC1032FPR PUBLICAT ION DATE M ARCH 2014 PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES - Executive Summary Human PapillomaVirus (HPV) Vaccine Sales Expected to Grow Modestly During the Forecast
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationGENETIC TECHNOLOGIES LIMITED DISEASE RISK ASSESSMENT ON A GLOBAL SCALE
GENETIC TECHNOLOGIES LIMITED DISEASE RISK ASSESSMENT ON A GLOBAL SCALE Forward Looking Statements This presentation may contain forward-looking statements within the meaning of Section 27A of the U.S.
More informationREFERENCE CODE GDHC386DFR PUBLICAT ION DATE M ARCH 2014 GARDASIL (PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC386DFR PUBLICAT ION DATE M ARCH 2014 GARDASIL (PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Gardasil: Key Metrics in Nine Major
More informationCorporate Presentation
Corporate Presentation March 2018 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking" statements within the meaning of the United States Private Securities
More informationBayer s Rivaroxaban Demonstrated Superior Protection Against Recurrent Venous Thromboembolism Compared with Aspirin in EINSTEIN CHOICE Study
News Release Not intended for U.S. and UK Media Bayer AG Communications and Public Affairs 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com New Late-Breaking Study Data Presented at ACC.17:
More informationAsia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures Outlook to 2020
Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Reference Code: GDMECR0107PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3
More informationMEGA-TRENDS IN DENTISTRY
2 MEGA-TRENDS IN DENTISTRY Position Yourself for Profitability by Ken Runkle Americaʼs Profitability Expert What are the major shifts and trends impacting the world of dentistry today? In our ongoing mission
More information